1. Home
  2. SEER vs TTRX Comparison

SEER vs TTRX Comparison

Compare SEER & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seer Inc.

SEER

Seer Inc.

HOLD

Current Price

$1.79

Market Cap

97.3M

Sector

Health Care

ML Signal

HOLD

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$4.01

Market Cap

107.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SEER
TTRX
Founded
2017
2015
Country
United States
United States
Employees
N/A
2
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
97.3M
107.2M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
SEER
TTRX
Price
$1.79
$4.01
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
406.3K
19.2K
Earning Date
05-13-2026
05-31-2026
Dividend Yield
N/A
N/A
EPS Growth
9.40
N/A
EPS
N/A
N/A
Revenue
$16,578,000.00
N/A
Revenue This Year
$2.14
N/A
Revenue Next Year
$25.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.99
N/A
52 Week Low
$1.65
$2.57
52 Week High
$2.41
$5.98

Technical Indicators

Market Signals
Indicator
SEER
TTRX
Relative Strength Index (RSI) 41.53 68.92
Support Level $1.71 $3.55
Resistance Level $1.84 $4.40
Average True Range (ATR) 0.08 0.20
MACD -0.02 0.04
Stochastic Oscillator 0.00 90.41

Price Performance

Historical Comparison
SEER
TTRX

About SEER Seer Inc.

Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: